



CLINICAL CARE OPTIONS[®]
HEPATITIS

Call to Arms: Tools for HCV Treaters to Maximize HCV Cure Rates and Advance Toward HCV Elimination

This program is supported by an independent educational grant from Gilead Sciences.



About These Slides

- § Please feel free to use, update, and share some or all of these slides in your noncommercial presentations to colleagues or patients
- § When using our slides, please retain the source attribution:



Slide credit: clinicaloptions.com

- § These slides may not be published, posted online, or used in commercial presentations without permission. Please contact permissions@clinicaloptions.com for details

Program Director

Norah Terrault, MD, MPH

Professor of Medicine and Surgery

Director, Viral Hepatitis Center

Division of Gastroenterology

University of California, San Francisco

San Francisco, California

Faculty

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Ira M. Jacobson, MD

Director of Hepatology
NYU Langone Medical Center
New York, New York

Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Christian B. Ramers, MD, MPH

Assistant Clinical Professor
Division of Infectious Diseases
Department of Medicine
UC San Diego School of Medicine
La Jolla, California
Assistant Medical Director
Division of Research/Special Populations
Family Health Centers of San Diego
San Diego, California

Faculty Disclosures

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, ContraVir, Gilead Sciences, Janssen, and Merck and funds for research support from Abbott, AbbVie, Gilead Sciences, Janssen, and Merck.

Ira M. Jacobson, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, Merck, and Trek; fees for non-CME/CE services from AbbVie, Gilead Sciences, Intercept, and Merck; and funds for research support from Genfit, Gilead Sciences, and Merck.

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and funds for research support from AbbVie and Gilead Sciences.

Christian B. Ramers, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, and Janssen; fees for non-CME/CE services from AbbVie, Gilead Sciences, Janssen, and Merck; and funds for research support from Gilead Sciences.

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Gilead Sciences and Merck and funds for research support from AbbVie, Gilead Sciences, and Merck.

Outline

§ The Path to 100% HCV Elimination

§ The Toolkit to Achieve Cure

§ Key Targets to Reach 100%

- Engaging the 50%: Increasing Screening and Diagnosis
- Treating the 33%: Expanding Therapy to the Previously Excluded
- Curing the 10%: Evolving Options for DAA-Experienced Patients